ERBB2 and triple-negative breast carcinoma: Apart from luminal subtypes, which tend to respond well to endocrine therapy, HER2 overexpression causes uncontrolled cell growth and is associated with higher recurrence and mortality in the absence of targeted therapy [43], while triple-negative breast cancers can result in the worst prognosis as they can only be treated with chemotherapy and radiotherapy.